<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215708</url>
  </required_header>
  <id_info>
    <org_study_id>278/06</org_study_id>
    <nct_id>NCT01215708</nct_id>
  </id_info>
  <brief_title>Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus</brief_title>
  <official_title>Effect of Tamsulosin and Nifedipine on the Elimination of Fragments After Extracorporeal Shock Waves Lithotripsy in Patients With Kidney Stones - a Prospective, Double-blind and Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators objective is to study if some drugs can improve the success rate of
      extracorporeal shockwave lithotripsy for renal stones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extracorporeal shockwave lithotripsy is one of the modalities of treatment of renal stones.
      It´s a machine that breaks the renal stones extracorporeally. Some drugs, like alpha blockers
      and calcium channel blockers, can improve the success rates of this procedure. Our objective
      is to study the real effects of two drugs, tamsulosin and nifedipine, compared to placebo, in
      the elimination of fragments after the extracorporeal shockwave lithotripsy treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of Tamsulosin and Nifedipine in the success rates after treatment of radiopaque renal stones between 5-20 mm with only one session of SWL</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of Tamsulosin and Nifedipine in the episodes of pain after treatment of radiopaque renal stones between 5-20 mm with only one session of SWL</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of Tamsulosin and Nifedipine in the velocity of elimination of fragments after treatment of radiopaque renal stones between 5-20 mm with only one session of SWL</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Renal Calculi</condition>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nifedipine retard 20mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tamsulosin 0,4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>tamsulosin 0,4mg every night for 30 consecutive days</description>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_label>tamsulosin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>secotex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  radiopaque renal stone, 5 to 20 mm, located at renal pelvis or superior or middle
             calix

        Exclusion Criteria:

          -  inferior calix, any contraindication for extracorporeal shockwave lithotripsy,
             pregnancy, coagulopathy, previous renal surgery, age under 18, abdominal aorta
             aneurism and urinary infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Srougi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinics Hospital of University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <last_update_submitted>October 5, 2010</last_update_submitted>
  <last_update_submitted_qc>October 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Fabio Carvalho Vicentini</name_title>
    <organization>University of Sao Paulo</organization>
  </responsible_party>
  <keyword>Kidney calculi</keyword>
  <keyword>Lithotripsy</keyword>
  <keyword>Calcium channel blockers</keyword>
  <keyword>Adrenergic alpha-antagonists.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

